Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. Subjects who received and completed the SHR-1918-301 study treatment in previous studies and were deemed to have therapeutic benefits by the researchers Exclusion Criteria: 1. Known to be allergic to the investigational drug or any component of the investigational drug, or to have experienced severe allergic reactions to other antibody drugs; 2. History of malignant tumors in the past 5 years; 3. There are serious concurrent diseases 4. Pregnant or lactating women; 5. The researchers determined that the subjects had poor compliance or any inappropriate factors for participating in this trial